Albert Labs International Corp

Albert Labs is a clinical-stage pharmaceutical company focused on developing psilocybin-based medicines for urgent mental health needs. The company utilizes a Real-World Evidence (RWE) approach to accelerate the regulatory approval process and provide faster access to therapies for patients with life-threatening illnesses. Its lead candidate, KRN-101, is being developed to treat cancer-related anxiety and distress. Albert Labs operates primarily in the United Kingdom and Europe, collaborating with major health institutions to conduct clinical trials. The company aims to integrate its psychedelic-assisted therapies into existing healthcare systems through a data-driven regulatory strategy.